Conexeu Sciences is trading 5.08% up at $3.63, with no confirmed company-specific catalyst identified for the October 9 move. - The latest company press release, dated October 6, concerned progress toward a planned FDA 510(k) submission; it was not a new announcement today. - The supplied biotech-sector context is negative and does not explain the gain. No clear same-direction market or company catalyst has been identified.